Welch Allyn to license Inovise Medical’s AUDICOR technology following a technology agreement

Welch Allyn, a leading global manufacturer of frontline medical products and solutions announced today that it has entered into a multi-year agreement with Inovise Medical, Inc., a privately held cardiac technology company. Under terms of the agreement, Welch Allyn will license Inovise Medical, Inc.’s AUDICOR® technology with improved cardiac information to accurately diagnose more patients with acute or previous silent heart attacks at the point of care.

“Integrating the Audicor® advanced electrocardiograph (ECG) analysis capability into our future line of cardiology products is an indication of our commitment to providing clinicians with the most advanced diagnostic capabilities to enhance patient care and improve outcomes,” said Julie Shimer, president and chief executive officer at Welch Allyn. “This partnership supports the overall business strategies of both companies and strengthens our mutual abilities to provide frontline caregivers with innovative solutions to patient care problems.”

Inovise Medical’s AUDICOR^® technology identifies subtle ECG features in patients that often present with atypical changes, such as those in female patients and patients with confounding conditions.

Peter Bauer, president of Inovise Medical, added, “Inovise’s AUDICOR^® technology was developed through years of focused research and algorithm development. We are pleased that through Welch Allyn’s successful products, more patients and clinicians will benefit from earlier diagnosis and treatment in the near future.”